Refractory Sweet Syndrome Treated with Anakinra

Area of Science:

• Dermatology
• Rheumatology
• Immunology

Background:

• Sweet syndrome (acute febrile neutrophilic dermatosis) is an uncommon inflammatory condition.
• It presents with painful skin lesions, fever, and elevated white blood cell counts.
• Often associated with infections, malignancies, pregnancy, or drug reactions.

Observation:

• A case study of a young female patient with a history of long-standing Sweet syndrome.
• The patient's condition was refractory to multiple standard treatments and various immunomodulators.

Findings:

• Treatment with anakinra led to the successful control of symptoms in this refractory case.
• Anakinra, an interleukin-1 receptor antagonist, demonstrated efficacy in managing severe Sweet syndrome.

Implications:

• Anakinra represents a potential therapeutic option for patients with severe or refractory Sweet syndrome.
• This case highlights the role of interleukin-1 blockade in managing complex dermatological conditions.
• Further research may explore anakinra's broader application in neutrophilic dermatoses.